Synergistic effect of paclitaxel and 4-hydroxytamoxifen on estrogen receptor-negative colon cancer and lung cancer cell lines

Anti-Cancer Drugs

Volumn 10, Issue 10, 1999, Pages 895-901

  Gu, Wen Zhen ^a   Chen, Zehan ^a   Tahir, Stephen K ^a   Rosenberg, Saul H ^a   Ng, Shi Chung ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Apoptosis; Cancer; Cell cycle; Combination treatment; Paclitaxel; Tamoxifen

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTINEOPLASTIC AGENT; CYTOCHROME C; ESTROGEN RECEPTOR; PACLITAXEL; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE G2 PHASE; CELL GROWTH; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME RELEASE; HUMAN; HUMAN CELL; LUNG CANCER; MITOCHONDRION; PRIORITY JOURNAL;

EID: 0033368984     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199911000-00005     Document Type: Article

References (21)

1. Crommentuyn KML, Schellens JHM, Berg VD, Beijnen JH. In-vitro metabolism of anti-cancer drugs, methods and applications: paclitaxel, docetaxel, tamoxifen and ifosfamide. Cancer Treat Rev 1998; 24: 345-66.
2. Horwitz SB. Mechanism of action of paclitaxel. Trends Pharmac Sci 1992; 13: 134-5.
3. Gelman K. Taxoids: paclitaxel and docetaxel. Lancet 1994; 344: 1271.
4. Kaye SB. Taxoids. Eur J Cancer 1995; 31A: 823-6.
5. Marty M, Extra JM, Cottu PH, Espie M. Prospects with docepaclitaxel in the treatment of patients with breast cancer. Eur J Cancer 1997; suppl 7: S26-9.
6. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334:1-6.
7. Huizing MT, Sewberath Misser VH, Pieters RC, et al. Taxanes: a new class of antitumor agents. Cancer Invest 1995; 13: 381-404.
8. Gu WZ, Tahir SK, Wang YC, et al. Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in-vitro and in-vivo. Eur J Cancer 1999; 35: 1394-1401.
9. Moasser MM, Sepp-Lorenzino L, Kohl NE, et al. Faesyl transferase inhibitors cause enhanced mitotic sensitivity to paclitaxel and epothilones. Proc Natl Acad Sci USA 1998; 95: 1369-74.
10. Jordan VC. Current approved uses of tamoxifen and recommendations in the United States. In: Jordan VC, ed. Tamoxifen, a guide for clinicians and patients. Huntington, NY: PRR 1996: 37-40.
11. Lerner LJ, Jordan VC. Development of antiestrogens and their use in breast cancer: Eighth Cain Memorial Award Lecture. Cancer Res 1990; 50: 4177-89.
12. Cuzick J, Baum M. Tamoxifen and contralateral breast cancer. Lancet 1985; ii: 282.
13. Fisher B. Highlights from recent National Surgical Adjuvant Breast and Bowel Project studies in the treatment and prevention of breast cancer. CA: Cancer J Clin 1999; 49: 159-77.
14. Kang Y, Cortina R, Perry RR. Role of c-myc in tamoxifen-induced apoptosis in estrogen-independent breast cancer cells. J Natl Cancer Inst 1996; 88: 279-84.
15. Kirk J, Syed SK, Harris AL, et al. Reversal of P-glycoprotein-mediated multidrug resistance by pure antioestrogens and novel tamoxifen derivatives. Biochem Pharmacol 1994; 48: 277-85.
16. Henderson C. Overviews of adjuvant tamoxifen therapy. In: Jordan VC, ed. Tamoxifen, a guide for clinicians and patients. Huntington, NY: PRR 1996: 41-63.
17. Creagan ET, Suman VJ, Dalton RJ, et al. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. J Clin Oncol 1999; 17: 1884-90.
18. Ferlini C, Scambia G, Distefano M, et al. Synergistic antiproliferative activity of tamoxifen and docetaxel on three oestrogen receptor-negative cancer cell lines is mediated by the induction of apoptosis. Br J Cancer 1997; 75: 884-91.
19. Yang J, Liu XS, Bhalla K, et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997; 275: 1129-32.
20. Berenhaum MC. Criteria for analyzing interaction between biologically active agents. Adv Cancer Res 1981; 35: 288-335.
21. Lin XS, Kim CN, Yang J, Jemmerson R, Wang XD. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996; 86: 147-57.